• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The hospitalizations in hypertrophic cardiomyopathy: “the dark side of the moon”.
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - August 14, 2020 Category: Cardiology Authors: Emanuele Monda, Giuseppe Limongelli Tags: Editorial Source Type: research

The hospitalizations in hypertrophic cardiomyopathy: “The dark side of the moon”
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - August 14, 2020 Category: Cardiology Authors: Emanuele Monda, Giuseppe Limongelli Tags: Editorial Source Type: research

Anticoagulation with a new oral anticoagulant in heart transplant recipients
Rivaroxaban is now accepted for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, and treatment and secondary prevention of deep vein thrombosis and pulmonary embolism. Nothing is known about the use of this new anticoagulant in transplanted patients. Here we report a series of heart transplant recipients treated with rivaroxaban and followed at our transplantation center.
Source: International Journal of Cardiology - July 25, 2013 Category: Cardiology Authors: Pierre Ambrosi, Bernard Kreitmann, William Cohen, Gilbert Habib, Pierre Morange Tags: Letters to the Editor Source Type: research